Therapeutic Areas · CNS and Neurology
Neurological disorders present unique operational challenges involving complex endpoints, long study durations, imaging, cognitive assessments and patient retention.
Overview
Neurological disorders present unique operational challenges involving complex endpoints, long study durations, imaging, cognitive assessments and patient retention.
Guosa Life Sciences supports CNS and neurology programs with specialized operational expertise, centralized assessments and long-term follow-up capabilities.
Areas of Expertise
Specialized Capabilities
Why GLS
Our integrated enterprise combines scientific depth, operational excellence and collaborative partnerships to support development across diverse and demanding research environments.
The capability
We support neuroscience programs across neurology and psychiatry: Alzheimer’s disease and other dementias, Parkinson’s disease, epilepsy, multiple sclerosis, stroke, depression and schizophrenia, from early phase through registration.
CNS studies live or die on measurement quality. Most primary endpoints are clinician-administered or patient-reported scales, which means the instrument, the rater and the language are all sources of variance before the intervention is considered. We treat rater performance as a monitored study parameter rather than a training event.
Regulatory considerations
Where a scale is used outside the language and culture it was validated in, a translated instrument is not automatically a validated one. Regulators expect linguistic validation and, for many instruments, evidence of cultural adaptation and measurement equivalence. This matters acutely in multi-country studies across Africa, Asia and Europe, where a single protocol may require a scale in six or more languages.
Rater qualification carries similar expectations: documented training against the specific instrument, certification before a rater scores a subject, and ongoing surveillance for drift across the study. Central review of scored assessments is increasingly expected where the primary endpoint is a rating scale, and the adjudication process needs defining in advance.
How an engagement runs
Instrument selection, language coverage and validation status assessed against the planned country footprint.
Linguistic validation where required, rater training and certification, and a central review process defined before activation.
Ongoing rater surveillance for drift, central review of assessments, and retraining where indicated.
Analysis with documented handling of rater variance and missing assessments.
What you receive
A scale validation and language coverage assessment. Rater certification records with ongoing surveillance. A central review and adjudication record. Analysis accounting for measurement variance.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
Other Therapeutic Areas
Preventive and therapeutic vaccines, pandemic preparedness.
ExploreEarly-phase through global Phase III.
ExploreMedical and aesthetic dermatology.
ExploreMedical and aesthetic dermatology.
ExploreAsthma, COPD and acute infection.
ExploreMaternal and reproductive health.
ExploreCardiovascular, diabetes and metabolic.
ExploreSmall, dispersed populations.
ExploreDevice and diagnostic studies.
ExplorePopulation and vaccination programs.
ExploreDiscuss your cns and neurology program with our multidisciplinary team.